Finerenone Reduced CV Events and CKD Progression
A randomized, double-blind, placebo-controlled trial in chronic kidney disease (CKD) and type 2 diabetes (T2D) concluded that treatment with finerenone reduced risks of CKD progression and cardiovascular (CV) events. Between September 2015 and June 2018, 5734 patients with CKD and T2D were randomly assigned in a 1:1 ratio to receive […]